Electroacupuncture and Rosiglitazone Combined Therapy as a Means of Treating Insulin Resistance and Type 2 Diabetes Mellitus: A Randomized Controlled Trial

Table 1

Baseline data obtained from the intention-to-treat patients in the experimental (TZD + EA) and placebo groups (TZD).

Groups	TZD + EA (𝑁=16)	TZD (𝑁=15)	𝑃-Value
Age (Years)	48±2	50±2	0.74 (NS)
Body Height (cm)	167±2	165±3	0.27 (NS)
Body Weight (Kg)	73±3	69±3	0.54 (NS)
BMI (Kg/m^2)	26±1	25±1	0.93 (NS)
Glucose (mmol/L)	9.4±0.5	9.1±0.6	0.51 (NS)
HbA1C (%)	8.10±0.45	8.15±0.44	1.00 (NS)
Cr (μmol/L)	71.6±2.7	69.8±5.3	0.20 (NS)
GPT (IU/L)	31±4	28±3	0.71 (NS)
Cholesterol (mmol/L)	5.1±0.3	4.9±0.3	0.44 (NS)
Triglyceride (mmol/L)	1.6±0.3	1.6±0.3	0.81 (NS)
Take OHA (Yes : No)	10 : 6	10 : 5	0.91 (NS)

All values are shown as mean ± SEM except for the use of oral hypoglycemic agents (OHA); TZD + EA = experimental group, who were patients that received 8 mg rosiglitazone and electroacupuncture; TZD = placebo group, who were patients that received 8 mg rosiglitazone only. Independent groups were compared using the nonparametric Mann-Whitney test. NS, means no significant difference, 𝑃>0.05.